{
  "ticker": "FHTX",
  "company_name": "Foghorn Therapeutics Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04879017",
      "title": "FHD-286 in Subjects With Metastatic Uveal Melanoma",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Metastatic Uveal Melanoma",
      "start_date": "2021-05-11",
      "completion_date": "2023-11-30",
      "enrollment": 0,
      "sponsor": "Foghorn Therapeutics Inc."
    },
    {
      "nct_id": "NCT07283094",
      "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia, Myelodysplastic Syndrome",
      "start_date": "2026-01",
      "completion_date": "2030-01",
      "enrollment": 0,
      "sponsor": "Montefiore Medical Center"
    },
    {
      "nct_id": "NCT04965753",
      "title": "FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Advanced Synovial Sarcoma",
      "start_date": "2021-08-17",
      "completion_date": "2023-12-04",
      "enrollment": 0,
      "sponsor": "Foghorn Therapeutics Inc."
    },
    {
      "nct_id": "NCT04891757",
      "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia",
      "start_date": "2021-06-14",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Foghorn Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 4,
    "by_phase": {
      "PHASE1": 4
    },
    "by_status": {
      "TERMINATED": 2,
      "NOT_YET_RECRUITING": 1,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Acute Myeloid Leukemia, Myelodysplastic Syndrome",
      "Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia",
      "Advanced Synovial Sarcoma",
      "Metastatic Uveal Melanoma"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:26.192640",
    "search_query": "Foghorn Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/search?term=Foghorn+Therapeutics+Inc."
  }
}